Phase Forward to Participate in October Industry Events

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate at three upcoming industry events in October including the 3rd Annual DIA Clinical Forum. Details are as follows:

At the 3rd Annual DIA Clinical Forum, October 19-21, in Nice, France, Phase Forward will share insights in four sessions:

Who: Andrea Bradbury, Vice President, Compliance and Quality, Phase Forward Clarix Products Group (Panelist)What: “A QA Perspective on XP in a Regulated Industry”When: Monday, October 19, 2:00-3:30 p.m. local time

Who: Joerg Dillert, Principal Consultant, Phase Forward (Panelist)What: “HL7 RIM – An Introduction for Non-technical Professionals”When: Tuesday, October 20, 4:00-5:30 p.m. local time

Who: Wayne Kubick, Vice President and Chief Quality Officer, Phase Forward Lincoln Safety Group (Panelist)What: “The Future of Clinical Data: The Evolving Impact of CDISC and HL7 on Data Management, Submission, and Pharmacovigilance”When: Tuesday, October 20, 4:00-5:30 p.m. local time

Who: William DuMouchel, Chief Statistical Scientist, Phase Forward Lincoln Safety Group (Panelist)What: “Safety Signal Detection in Longitudinal Observational Data”When: Wednesday, October 21, 11:00 a.m.-12:30 p.m. local time

Additionally, at the 2009 SCDM Annual Conference, October 4-6, in Seattle, WA, Phase Forward will exhibit its full solution set at booth # 208. Phase Forward will also exhibit its clinical data analysis and reporting automation and compliance technologies at booth # 17 at the PhuSE 2009 Conference, October 19-21, in Basel, Switzerland.

Members of the media interested in speaking with Phase Forward at the DIA Clinical Forum and/or the PHuSE Conference should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com, and for the SCDM Conference, Meghan Locke at 781-672-3147 or mlocke@chenpr.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2024 to Aug 2024